ClinicalTrials.gg
RecruitingNCT04893564SLP-raresUpdated Sep 9, 2025

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

An interventional study of bone marrow sample and blood sample in Waldenstrom's Disease and Waldenstrom Macroglobulinemia, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Waldenstrom Macroglobulinemia with a site in France — 11 open to participants now, 16 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · France.

Planned enrollment
27th of 36
90 · median 130
Started
2022
with 3 others
No phase
4 of 41
2 open now
Primary completion
2027-07
later than 10 of 15 live
Registered
26th of 41
by date
Lead sponsor
2 of 41
Centre Hospitalier Universitaire, Amiens

Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 26th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

11 of the 41 studies in Waldenstrom Macroglobulinemia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Waldenstrom Macroglobulinemia with a site in France, or all of them as a file.
02

Study summary

Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. This chronic lymphoproliferative disorder requires treatment only in case of symptoms, according to accurate criteria described during the second Workshop on WM i.e. in case of cytopenia, bulky organomegaly, immunological or physicochemical consequences of the presence of IgM in circulating blood. A MYD88 mutation, typically a MYD88(L265P), is found in 90% of WM patients. Other gene abnormalities have been observed, the most frequent is a mutation in the CXCR4 gene. Overall, gene mutations in WM involve only a limited number of signalling pathways, yielding the activation of NFkB, namely : the TLR and MYD88 pathway (with an activation of NFkB and BTK in case of MYD88(L265P) mutation), the BCR pathway (involving btk and associated with activations of both NFkB, and erk akt pathway) and the CXCR4 pathway (CXCR4 is a receptor of CXCL12, it is also associated with activations of ERK/MAPK and PI3K). Abnormalities of some of genes, such as TP53, of the expression of the protein CXCL13 and genes involved in the interleukin 6 secretion have been associated with some clinical characteristics.

The purpose of this project is to define the prognostic role of the detection of circulating tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first 3 years after the first 6 months of treatment.

03

Conditions studied

  • Waldenstrom's Disease
  • Waldenstrom Macroglobulinemia

Keywords

  • Waldenstrom's Disease
  • Waldenstrom Macroglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with WM according to diagnostic criteria
  • Patients with WM followed in one of the centre of North-Western region.
  • Patients requiring or subsequent-line therapy
  • Patients agreement for giving .
  • Social insurance system affiliation

Exclusion criteria

Exclusion Criteria:

  • Patients with another chronic B-cell
  • patients with other lymphoplasmacytic proliferations
  • patients with marginal zone lymphoma.
  • Patients with WM and histologic transformation
  • Absence of
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Interventions

  • Biologicalbone marrow sample

    8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.

  • Biologicalblood sample

    20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.

06

What researchers measure

Primary outcomes

  1. association between circulating tumoral DNA detection and progression-free survival

    To define the prognostic role of the detection of circulating tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first 3 years after the first 6 months of treatment.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • CHU Amiens
    Amiens, 80480, France
    Recruiting
    • Pierre MOREL, MD · Contactmorel.pierre@chu-amiens.fr · 03.22.45.54.19
    • Fabrice JARDIN, MD · Principal investigator
    • Xavier TROUSSARD, MD · Principal investigator
    • Gandhi DAMAJ, MD · Principal investigator
    • Stéphanie POULAIN, MD · Principal investigator
    • Daniela ROBU, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Jul 2027, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 19, 2021
StartActual
May 16, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893564
Collaborators
Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens
Responsible party
Sponsor
First posted
May 19, 2021
Start date
May 16, 2022
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 9, 2025

Study contacts

Pierre MOREL, MD
Contact
morel.pierre@chu-amiens.fr
03.22.45.54.19

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion